GlassScriptPhysician profile
Zbigniew Aniol
NPI 1871582486
$1,998.70
in general payments reported to CMS, 2019-2025
28 companies · $165 in 2025
The $165 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $126 · 2020: $268 · 2021: $322 · 2022: $372 · 2023: $464 · 2024: $282 · 2025: $165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $911.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $910.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $437.64 | 2019-2022 | |
| Coopersurgical, INC. | $208.51 | 2019-2024 | Paragard T 380a, Paragard T 380a |
| Exact Sciences Corporation | $148.59 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $144.80 | 2023-2025 | Veozah |
| Mayne Pharma Commercial LLC | $138.83 | 2023-2025 | |
| Aspira Women'S Health INC | $96.88 | 2020-2022 | |
| Agile Therapeutics, INC. | $95.80 | 2021-2023 | Twirla |
| Hologic Sales and Service, LLC | $95.08 | 2020-2025 | Thinprep 2000 Processor, Aptima, Fluent Fluid Management System |
| Amgen INC. | $75.45 | 2021-2025 | Evenity, Prolia |
| Merck Sharp & Dohme LLC | $66.25 | 2023-2024 | Gardasil 9, Gardasil |
| Merz North America, INC. | $56.39 | 2021-2023 | Xeomin |
| Myovant Sciences INC. | $56.19 | 2022 | |
| Glaxosmithkline, LLC. | $38.80 | 2023-2025 | Bexsero, Pediarix, Rotarix |
| Scynexis, INC. | $35.50 | 2022 | |
| Roche Diagnostics Corporation | $33.68 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $30.00 | 2023 | |
| Gynesonics, INC. | $25.43 | 2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Sumitomo Pharma America, INC. | $24.85 | 2023 | Myfembree |
| Bayer Healthcare Pharmaceuticals INC. | $23.88 | 2024 | |
| Shield Therapeutics INC | $21.27 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $21.07 | 2023 | Exparel |
| Ethicon US, LLC | $19.95 | 2021 | |
| Exeltis, USA INC. | $19.67 | 2023 | Slynd |
| Organon LLC | $19.66 | 2023 | Nexplanon |
| Amag Pharmaceuticals, INC. | $18.93 | 2021 | |
| Allergan, INC. | $17.68 | 2019 | |
| Galderma Laboratories, L.P. | $14.46 | 2021 | |
| Aesculap, INC. | $13.46 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zbigniew Aniol listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.